Optically active chiral diphosphine ligands

Abstract

A (R) or (S) chiral diphosphine of formula (I): 1

Description

[0001] The object of the present invention is the use of chiral diphosphines as optically active ligands for the preparation of diphosphino-metal complexes. The invention also pertains to the diphosphino-metal complexes comprising a chiral diphosphine as ligand and the asymmetric catalysis processes employing these complexes. The invention envisages more particularly the use of these diphosphino-metal complexes in asymmetric hydrogenation or isomerization processes for the synthesis of organic products of specified chirality.

[0002] Known in the prior art are different ligands used for the synthesis of diphosphino-metal complexes having catalytic properties in asymmetric hydrogenation. One can cite, e.g., the compound BINAP described by the Takasago company in European patent applications no. 444 930 and no. 295 109, the compound MeOBIPHEP described by the Hoffmann-La Roche company in European patent application no. 398132 and PCT application no. WO 93/15090.

[0003] The applicant has now developed new diphosphino-metal complexes comprising a chiral diphosphine as optically active ligand particularly useful for the synthesis of organic products of specified chirality with very high yields and enantioselectivity.

[0004] Thus the invention has as its object the use of an (R) or (S) chiral diphosphine of formula (I):

[0005] /insert formula (I), top of page 2/

[0006] in which:

[0007] R and R1, which can be identical or different, represent an optionally saturated C1-10 alkyl group, an optionally saturated C3-9 cycloalkyl group, a C5-10 aryl group, said groups being optionally substituted by a halogen, an hydroxy, a C1-5 alkoxy, an amino such as NH2, NHR4, N(R4)2, a sulfino, a sulonfyl, with R4 representing an alkyl, an alkoxy or an alkylcarbonyl, said cycloalkyl, aryl groups optionally comprising one or more heteroatoms such as O, N, S, Si,

[0008] or R and R1 together represent an optionally saturated C2-6 substituted alkyl group, an optionally saturated C3-9 cycloalkyl group, a C5-10 aryl group, said cycloalkyl or aryl groups being optionally substituted by a C1-5 alkyl, a halogen, an hydroxy, a C1-5 alkoxy, an amino such as NH2, NHR4, N(R4)2, a sulfino, a sulonfyl, with R4 representing an alkyl, an alkoxy or an alkylcarbonyl, said carbocycle, aryl groups optionally comprising one or more heteroatoms such as O, N, S, Si,

[0009] R2 and R3, which can be identical or different, represent an optionally saturated C3-8 cycloalkyl group, a C6-10 aryl group, said groups being optionally substituted by a halogen, an hydroxy, a C1-5 alkoxy, an amino such as NH2, NHR4, N(R4)2, a sulfino, a sulonfyl, with R4 representing an alkyl, an alkoxy or an alkylcarbonyl, said alkyl, cycloalkyl, aryl groups optionally comprising one or more heteroatoms such as O, N, S, Si,

[0010] or R2 and R3 together form an optionally saturated C4-8 carbocycle group, a C6-10 aryl group, said groups being optionally substituted by a halogen, an hydroxy, a C1-5 alkoxy, an amino such as NH2, NHR4, N(R4)2, a sulfino, a sulonfyl, with R4 representing an alkyl, an alkoxy or an alkylcarbonyl, said alkyl, cycloalkyl, aryl groups optionally comprising one or more heteroatoms such as O, N, S, Si,

[0011] as optically active ligand for preparation of a diphosphino-metal complex.

[0012] The chiral diphosphines of formula (I) can be used according to the invention for preparation of many types of diphosphino-metal complexes.

[0013] A first group of diphosphino-metal complexes prepared using the chiral diphosphines of formula (I) according to the invention responds to formula (II) below:

MxHyXz(L)2(Sv)p  (II)

[0014] in which,

[0015] M represents a metal such as ruthenium, rhodium or iridium;

[0016] X represents a halogen such as chlorine, bromine, fluorine or iodine;

[0017] Sv represents a tertiary amine, a ketone, an ether;

[0018] L represents a (R) or (S) chiral diphosphine of formula (I) above;

[0019] y is a whole number equal to 0 or 1;

[0020] x is a whole number equal to 1 or 2;

[0021] z is a whole number equal to 1 or 4;

[0022] p is a whole number equal to 0 or 1.

[0023] Among the diphosphino-metal complexes of formula (II), the invention envisages more particularly the complexes of formulas (IIA) and (IIB).

[0024] The complexes of formula (IIA) are those in which y=0, and then x=2, z=4 and p=1.

[0025] These complexes respond to formula (IIA) below:

M2X4L2(Sv)  (IIA)

[0026] in which M, X, L and Sv have the same meanings as in formula (II).

[0027] The following can be cited as examples of complexes of formula (IIA):

[0028] Ru4Cl2[(R) or (S) CH3CHOO-Binap]2.N(Et)3, also designated di[2,2′-bis(diphenylphosphino) (R) or (S)-6,6′-diacetoxybiphenyl]-tetrachloro diruthenium triethylamine,

[0029] Ru4Cl2((Me)2CHCOO-Binap)2.N(Et3), also designated di[2,2′-bis(diphenylphosphino) (R) or (S)-6,6′-di-isobutanoyloxybiphenyl]-tetrachloro diruthenium triethylamine,

[0030] Ru4Cl2((CH3)3CCOO-Binap)2.N(Et)3, also designated di[2,2′-bis(diphenylphosphino) (R) or (S)-6,6′-ditrimethylacetoxybiphenyl]-tetrachloro diruthenium triethylamine,

[0031] Ru4Cl2((Me)2CHCH2COO-Binap)2.N(Et)3,

[0032] Ru4Cl2(CH3COO-Binap)2.CO(Me)2,

[0033] Ru4Br2(CH3COO-Binap)2.N(Et)3,

[0034] Ru4Br2((Me)2CHCOO-Binap)2.N(Et)3,

[0035] Ru4Br2((CH3)3CCOO-Binap)2.N(Et)3,

[0036] Ru4Br2((Me)2CHCH2COO-Binap)2.N(Et)3,

[0037] Ru4Br2(CH3COO-Binap)2.CO(Me)2,

[0038] Ru4Br2((Me)2CHCOO-Binap)2.CO(Me)2,

[0039] Ru4Br2((CH3)3CCOO-Binap)2.CO(Me)2,

[0040] Ru4Br2((Me)2CHCH3COO-Binap)2.CO(Me)2,

[0041] Ru4Br2(C6H5COO-Binap)2.CO(Me)2,

[0042] Ru4Br2(C6H11COO-Binap)2.CO(Me)2,

[0043] Ru4Br2(C4H3OCOO-Binap)2.CO(Me)2,

[0044] Ru4Br2(CH3OCH2COO-Binap)2.CO(Me)2,

[0045] The complexes of formula (IIB) are those in which y=1 and then x=1, z=1 and p=0.

[0046] These complexes respond to formula (IIB) below:

MHXL2  (IIB)

[0047] in which M, X and L have the same meanings as in formula (II) and H represents a hydrogen atom.

[0048] A second group of diphosphino-metal complexes prepared using the chiral diphosphines of formula (I) according to the invention responds to formula (III) below:

MXj(Ar)mLYn  (III)

[0049] in which,

[0050] M, X, L have the same meanings as in formula (II);

[0051] Ar represents an olefin such as ethylene, 1,3-butadiene, cyclohexadiene, norbonadiene, cycloocta-1,5-diene, a pi-allyl, a nitrile such as acetonitrile, an arene of formula (IV):

[0052] /insert formula (IV), bottom of page 5/

[0053] in which R5, R6, R7, R8, R9 and R10, which can be identical or different, are selected from among a hydrogen atom, a C1-5 alkyl group, an isoalkyl group, a tertioalkyl group, an alkoxy group, said groups comprising one or more heteroatoms such as O, N and Si;

[0054] Y represents an anion, such as CIO4—, BF4—, PF6—;

[0055] j is a whole number equal to 0 or 1;

[0056] m is a whole number equal to 1, 2 or 4;

[0057] n is a whole number equal to 1 or 2.

[0058] A third group of diphosphino-metal complexes prepared using the chiral diphosphines of formula (I) according to the invention responds to formula (V) below:

[MX(P(R11)2(R12))L]2X  (V)

[0059] in which

[0060] M, X and L have the same definitions as in formula (II), and R11 and R12, which can be identical or different, represent a phenyl or a phenyl substituted by an alkyl, an alkoxy or a dialkylamino.

[0061] A fourth group of diphosphino-metal complexes prepared using the chiral diphosphines of formula (I) according to the invention responds to formula (VI) below:

M(L)Z2  (VI)

[0062] in which,

[0063] M and L have the same meanings as in formula (II) and Z represents an acetate group of formula R13COO—, a diacetate group of formula —OOCR13COO—, an aminoacetate group of formula R13CH(NH2)COO—, in which R13 represents a C1-4 alkyl, a C1-4 halogenoalkyl, an optionally substituted phenyl.

[0064] A fifth group of diphosphino-metal complexes prepared using the chiral diphosphines of formula (I) according to the invention responds to formula (VII) below:

[M(L)WXk]nZ′p  (VI)

[0065] in which:

[0066] M, L and X have the same meanings as in formula (II);

[0067] W represents zinc, aluminum, titanium or tin;

[0068] Z′ represents:

[0069] either an acetate group of formula R14COO— in which R14 represents a C1-4 alkyl, a C1-4 halogenoalkyl, an optionally substituted phenyl, and in this case n=1 and p=2, and when W is Zn then k=2, when W is Al then k=3, and when W is Ti or Sn then k=4,

[0070] or a tertiary amine, such as triethylamine, and in this case n=2 and p=1, and when W is Zn then k=4, when W is Al then k=5, and when W is Ti or Sn then k=6.

[0071] A sixth group of diphosphino-metal complexes prepared using the chiral diphosphines of formula (I) according to the invention responds to formula (VIII) below):

MH(L)2Y  (VIII)

[0072] in which H represents a hydrogen atom, M and L have the same meanings as in formula (II); Y represents an anion such as CIO4—, BF4—, PF6—.

[0073] A seventh group of diphosphino-metal complexes prepared using the chiral diphosphines of formula (I) according to the invention responds to formula (IX) below:

M(L)Y2  (IX)

[0074] in which M and L have the same meanings as in formula (II) and Y represents an anion such as CIO4—, BF4—, PF6—.

[0075] An eighth group of diphosphino-metal complexes prepared using the chiral diphosphines of formula (I) according to the invention responds to formula (X) below:

M(L)2Y  (X)

[0076] in which M and L have the same meanings as in formula (II) and Y represents an anion such as CIO4—, BF4—, PF6—.

[0077] The (R) or (S) chiral diphosphines (I) can be prepared by processes well known by the expert in the field from compounds of formula (XI):

[0078] /insert formula (Xl), bottom of page 8/

[0079] in which R2 and R3 have the same meanings as in formula (I).

[0080] These processes consist of bringing together a compound of formula (XI) and a compound derived from an acid halide of formula RCOX or R1COX, in which R and R1 have the same meanings as in formula (I) and X has the same meaning has in formula (II).

[0081] The compound of formula (XI) is prepared according to the process described in PCT patent application no. WO 93/15090 from the compound of formula (XII):

[0082] /insert formula (XII), top of page 9/

[0083] in which R2 and R3 have the same meanings as in formula (I).

[0084] The complexes of formulas (II), (III) and (V) can be prepared by analogy according to methods described in the prior art.

[0085] Thus, according to the process described in European patent application no. 174 057, the complexes of formula (II) can be prepared from a compound of formula (XIII):

MX2(COD)2  (XIII)

[0086] in which M and X have the same meanings as in formula (II) and COD represents cyclooctadiene.

[0087] Similarly, according to the process described in European patent application no. 366,390, the complexes of formula (III) can be prepared from a compound of formula (XIV):

[MX2(Ar)]2  (XIV)

[0088] in which M, X and Ar have the same meanings as in formula (III).

[0089] Finally, according to the process described in European patent application no. 470 756, the compounds of formula (V) can be prepared from a compound of formula (XV):

[MX(P(R11)2(R12)) (DMA)]2 X  (XV)

[0090] in which M, X, R11 and R12 have the same definitions as in formula (V) and DMA represents dimethylacetamide.

[0091] The complexes of formulas (VI), (VII), (VIII), (IX) and (X) can be prepared by analogy according to methods described in the prior art.

[0092] Thus, the complexes of formulas (VI and (VII) can be obtained from compounds of formula (IIA) by analogy by the processes described in European patent applications no. 245 960 and no. 271 310. The complexes of formulas (VIII), (IX) and (X) can be obtained from compounds of formula (IIB) by analogy by the processes described in European patent applications no. 256 634, no. 245 959 and no. 271 310.

[0093] The present invention also pertains to the diphosphino-metal complexes of formulas (II), (III), (V), (VI), (VII), (VIII), (IX) and (X) as well as their use as catalyst in asymmetric catalysis processes. The invention envisages more particularly their use in asymmetric hydrogenation or asymmetric isomerization processes.

[0094] The invention pertains more specifically to their use in a process for asymmetric hydrogenation of unsaturated compounds carrying functional groups of formula (XVI) below:

[0095] /insert formula (XVI), top of page 11/

[0096] in which:

[0097] A and B are different and selected from among a C1-5 alkyl group, an aryl group, a C1-7 hydroxycarbonyl group, a C1-7 alkoxycarbonyl group, a C1-10 aryloxycarbonyl group, a C1-7 halogenoalkyl group, a heteroaryl group, an optionally saturated cycloalkyl group, said alkyl, aryl, cycloalkyl groups optionally comprising one or more substituents selected from among a halogen such as chlorine, fluorine, bromine, an —NO2 group, a C1-5 alkyl, a C1-5 alkoxy, an optionally fused C1-7 cycloalkyl, an optionally fused aryl group, possibly substituted by a halogen, a C1-5 alkyl, a C1-5 alkoxy, said alkyl, cycloalkyl, aryl groups optionally comprising one or more heteroatoms such as O, N or Si.

[0098] Or A and B together form a C2-6 substituted alkyl group, an optionally saturated C3-9 cycloalkyl group, a C5-10 aryl group, said groups optionally being substituted by a C1-5 alkyl, a halogen, an hydroxy, a C1-5 alkoxy, an amino such as NH2, NHR4, N(R4)2, a sulfino, a sulfonyl, in which R4 represents an alkyl, an alkoxy or an alkylcarbonyl, said alkyl, cycloalkyl, aryl groups optionally comprising one or more heteroatoms such as O, N, S, Si;

[0099] Q represents an oxygen, an —NR16, —NOR16 or —C(R16)2 group, in which R16 is selected from among a C1-5 alkyl, an aryl group, a heteroaryl group substituted by a C1-4 alkyl.

[0100] Among the compounds of formula (XVI), one can cite as nonlimitative examples the following compounds: the ene-acid or ester derivatives, the ene-alcohol or ether derivatives, the ene-amide derivatives, the ene-amino derivatives, the beta-ketoacid or ester derivatives, the gamma-ketoacid or ester derivatives, the beta, gamma-diketoacid or ester derivatives, the alpha-amid-beta-ketoacid or ester derivatives, the halogeno-ketone derivatives, the hydroxy or alkoxy-ketone derivatives, the imine derivatives.

[0101] A preferred asymmetric hydrogenation process according to the invention comprises the treatment of a compound of formula (XVI), in a suitable solvent, in the presence of a catalytic complex of formula (II), (III), (V), (VI), (VII), (VII), (IX) or (X) as catalyst under the following preferred operating conditions:

[0102] A temperature between 0 and +150° C.

[0103] A hydrogen pressure between 1 and 20 bar or between 1 and 100 bar.

[0104] An amount of catalyst in relation to the amount of substrate comprised between 1/50,000 and 1/10, preferably between 10/10,000 and 1/10, and most preferably between 10/100 and 1/10.

[0105] The duration of hydrogenation will generally be equal to or greater than 1 hour. As a function of the substrate and the catalyst, it could be between 1 hour and 70 hours.

[0106] Any solvent can be used in isolation or mixture such that it will dissolve the substrate and not affect the reaction. Among the solvents that can be used in the above process, one can cite water, a hydrocarbon such as hexane, heptane, octane, nonane, decane, benzene, toluene and xylene, an ether such as tetrahydrofuran, tetrahydropyran, dioxane, dimethoxyethane, diisopropyl ether and diethylene glycol dimethyl ether, an ester such as a formate or an alkyl acetate such as ethyl formate, ethyl acetate, butyl acetate and ethyl propionate, a ketone such as acetone, diethyl ketone, diisopropyl ketone, methylisobutyl ketone, methylethyl ketone and acetylacetone, an alcohol such as methanol, ethanol, n-propanol and iso-propanol, a nitrile such as acetonitrile, an alkyl halide such as dichloromethane, chloroform and 1,2-dichloroethane, an amine such as dimethylamine, triethylamine, diisobutyl amine, triethylamine, N-methyl piperidine, ethyl diisopropyl amine, N-methlycyclohexyl amine and pyridine, an organic acid such as acetic acid, propionic acid and formic acid, an amide such as dimethyl formamide and N-methyl formamide.

[0107] When implementing the reaction, it is recommended to use the substrate at a concentration in the solvent of 0.1 to 2 moles/liter.

[0108] Other advantages and characteristics of the invention will become apparent from the examples below which are presented on a nonlimitative basis.

I—Preparation of the Ligands

EXAMPLE 1

Preparation of the Ligand (R)-HOBIPHEP: (R)-6,6′-Dihydroxybiphenyl-2,2′-diyl bis(Diphenyl Phosphine)

[0109] The process described in the PCT patent application no. WO 93/15090 was applied.

[0110] The compound (R)-HOBIPHEP was obtained with a quantitative yield.

EXAMPLE 2

Preparation of the Ligand (R)-CH3COOBIPHEP (Summary A): (R)-6,6′-Acetoxybiphenyl-2,2′-diyl bis(Diphenyl Phosphine).

[0111] Under nitrogen in a 250-ml four neck flask, (R)-HOBIPHEP (5.65 g; 1.01·10−2 mol) was suspended in 100 ml of DMF. K2CO3 (7 g) was added at 20/24° C. After 10 minutes of agitation, acetyl chloride (1.7 g; 2.14·10−2 mol) was added drop by drop. This was maintained at a temperature of 24/25° C. for 48 hours.

[0112] The reaction medium was concentrated. The residue was taken up with a solution of 220 ml of ethyl acetate and 50 ml of water.

[0113] After decantation, the organic phase was washed with a solution of sodium chloride (3 times 30 ml). The organic phase was dried, filtered then concentrated under vacuum.

[0114] This produced 4.5 g of product in the form of clear maroon crystals.

[0115] The product was purified by column chromatography. Eluent: CH2Cl2/hexane (1/2).

[0116] This yielded 3.35 g of product in the form of white crystals.

[0117] Yield: 59% of purified product.

[0118] [α]D23:+52.4°;

[0119] 1 H NMR spectrum: 7.4-7.05 ppm (m, 26H, H arom.); 1.7 ppm (S, 6H, CH3CO).

[0120] 13 C NMR spectrum: 168.9 (CO); 122.8-148.9 (C arom.); 20.5 (C methyl).

EXAMPLE 3

Preparation of the Ligand (R)-(CH3)2CHCOOBIPHEP (Summary B): (R)-6,6′-Isobutanoyloxy Biphenyl-2,2′-diyl bis(Diphenyl Phosphine)

[0121] In a 250-ml four neck flask under agitation, (R)-HOBIPHEP (4 g; 7.21·10−3 mol) was suspended in 72 ml of THF. The medium was cooled to −20° C. and NaH (0.61 g; 0.025 mol) was added. The medium was left under agitation at −20° C. for 1 hour. The medium was cooled to −30° C. and then 98% isobutyric acid chloride (1.6 ml; 0.025 ml) was added drop by drop. The medium was allowed to heat up to room temperature, i.e., 20° C. (at the end of 1 hour). The medium was hydrolyzed with 50 ml of water. The reaction was exothermal. Extraction was performed with 40 ml of ethyl acetate. The organic phase was washed with water (20 ml) then with an aqueous solution of sodium chloride (2 times 20 ml). The organic phase was dried, filtered and then concentrated under vacuum.

[0122] 5.6 g of product was obtained in the form of a maroon gum.

[0123] The product was purified by column chromatography. Eluent: CH2Cl2/hexane (1/2).

[0124] 2.3 g of product was obtained in the form of white crystals.

[0125] Yield: 31.4% of purified product.

[0126] [α]D23=:+49.6°;

[0127] 1 H NMR spectrum: 7.2-7.55 ppm (m, 26H, H arom.); 2.2-2.35 ppm (m, 2H, —CH—), 0.8-1.05 ppm (m, 12H, (CH3)2—).

[0128] 13 C NMR spectrum: 175 (CO); 123-149 (C arom.); 34 (CH—); 19 (C methyl).

EXAMPLE 4

Preparation of the Ligand (R)-(CH3)3CCOOBIPHEP (Summary C): (R)-6,6′-Tertiobutanoyloxybiphenyl-2,2′-diyl bis(Diphenyl Phosphine).

[0129] Employing the same procedure as example 2.

[0130] Yield: 58%.

[0131] 1 H NMR spectrum: 7.05-7.4 ppm (m, 26 H, H arom.); 0.8 ppm (m, 18H, (CH3)).

[0132] 13 C NMR spectrum: 176 (CO); 122.8-149 (C arom.); 39.5 (C); 28 (C methyl).

EXAMPLE 5

Preparation of the Ligand (R)-(CH3)2CHCH2COOBIPHEP (Summary D): (R)-6.6′-Isovaleroyloxybiphenyl-2,2′-diyl bis(Diphenyl Phosphine)

[0133] Employing the same operating mode as example 3.

[0134] The reaction medium was left for 24 hours at 20° C. before hydrolysis.

[0135] 5.1 g of product was obtained in the form of an oil.

[0136] Purification was performed by column chromatography. Eluent: CH2Cl2/hexane (1/2).

[0137] 1.7 g of product was obtained in the form of white crystals.

[0138] Yield: 37% of purified product.

[0139] 1 H NMR spectrum: 7.2-7.55 ppm (m, 26H, H arom.); 1.85-2.05 ppm (m, 6H, CH2CH—), 0.95 ppm (d, 12H, (CH3)2—).

[0140] 13 C NMR spectrum: 171 (CO); 123-149.4 (C arom.); 43.1 (CH−); 25.6 (CH3); 22.7 (C methyl).

EXAMPLE 6

Preparation of the Ligand (R)-C6H5COOBIPHEP (Summary E): (R)-6,6′-Benzoyloxybiphenyl-2,2′-diyl bis(Diphenyl Phosphine)

[0141] In a 500-ml four neck flask NaH (2.6 g; 0.108 mol) was added to THF (64 ml).

[0142] (R)-HOBIPHEP (0.0257 mol) was added at 20° C. in solution in DMF (64 ml) for 45 minutes. It was left under agitation at 20° C. for 1 hour. The medium was then cooled to 40° C. Benzoyl chloride (8.18 ml, source: Fluka) was introduced drop by drop for 20 minutes. The medium was maintained at −40/45° C. for 45 minutes.

[0143] A 10% solution of hydrochloric acid (75 ml) was added.

[0144] The temperature was allowed to climb to 0° C. during the addition.

[0145] Upon termination of the hydrolysis, the temperature was brought to room temperature. The medium was extracted with ethyl acetate (50 ml and 40 ml). The organic phase was washed with water (2 times 20 ml). The organic phase was dried, filtered and then concentrated under vacuum.

[0146] The anticipated product was obtained in the form of a maroon oil.

[0147] Purification was performed by column chromatography. Eluent: hexane then toluene.

[0148] The product was obtained in the form of white crystals.

[0149] Yield: 55.2% of purified product.

[0150] 1 H NMR spectrum: 7-7.55 ppm (m, H arom.).

[0151] 13 C NMR spectrum: 164 (CO); 123-149 (C arom.).

EXAMPLE 7

Preparation of the Ligand (R)-C6H11COOBIPHEP (Summary 7): (R)-6,6′-Cyclohexanoylbiphenyl-2,2′-diyl bis(Diphenyl Phosphine)

[0152] Following the same procedure as that of example 6 but without purification by column chromatography.

[0153] The product was obtained in the form of white crystals.

[0154] Yield: 52.5% of product.

[0155] 1 H NMR spectrum: 7.15-7.5 ppm (m, 26H, H arom.); 1.9 ppm (m, 2H, —CH—), 1-1.6 ppm (m, 20H, —(CH2)—).

[0156] 13 C NMR spectrum: 172 (CO); 123-149.5 (C arom.); 43 (CH—); 26 and 28 ppm (CH2).

EXAMPLE 8

Preparation of the Ligand (R)-(C4H3O)COOBIPHEP (Summary G): (R)-6,6′-2-Furanoyloxybiphenyl-2,2′-diyl bis(Diphenyl Phosphine)

[0157] Following the same procedure as that of example 6 with purification by column chromatography. Eluent: CH2Cl2.

[0158] The product was obtained in the form of white or pale yellow crystals.

[0159] Yield: 84.2% of purified product.

[0160] 1 H NMR spectrum: 7.6-6.35 ppm (m, H arom. +H furyl).

[0161] 13 C NMR spectrum: 156 (CO); 110-149 (C arom.).

EXAMPLE 9

Preparation of the Ligand (R)-CH3OCH2COOBIPHEP (Summary H): (R)-6,6′-Methoxyacetyloxybiphenyl-2,2′-diyl bis(Diphenyl Phosphine)

[0162] Following the same procedure as that of example 6 without purification by column chromatography.

[0163] The product was obtained in the form of white or pale yellow crystals.

[0164] Yield: 34.8% of product.

[0165] 1 H NMR spectrum: 7.4-7.08 ppm (m, 26H, H arom.); 3.6 ppm (s, 4H, —OCH2O—), 3.25 ppm (s, 6H, CH3O—).

[0166] 13 NMR spectrum: 169 (CO); 123-149 (C arom.); 69 (CH2O—); 60 (C methoxy).

II-Preparation of catalysts
Exp. no.	Formula R = R1	Summary	Name
10	CH3CO2	(R)-cA1	(R)-acetyloxyBIPHEPRuBr2 acetone
11	CH3CO2	(R)-cA	(R)-acetyloxyBIPHEPRu(OAC)2
12	(CH3)2CHCO2	(R)-cB	(R)-iso-propanoyloxyBIPHEPRu(OAC)2
13	(CH3)2CHCO2	(R)-cB	(R)-iso-propanoyloxyBIPHEPRuBr2
14	(CH3)3CCO2	(R)-cC	tertio-butanoyloxyBIPHEPRuBr2
15	(CH3)2CHCH2CO2	(R)-cD	iso-valeroyloxyBIPHEPRuBr2
16	C6H5CO2	(R)-cE	benzoyloxyBIPHEPRuBr2
17	C6H11CO2	(R)-cF	cyclohexanoyloxyBIPHEPRuBr2
18	C4H3OCO2	(R)-cG	2-furanoyloxyBIPHEPRuBr2
19	CH3OCH2CO2	(R)-cH	methoxyacetyloxyBIPHEPRuBr2

EXAMPLE 10

Preparation of the Catalyst: the Complex [RuBr2(R)-C H3COOBIPHEP)]2.Acetone

[0167] The following were introduced into a hydrogenation chamber: the ligand (R)—CH3COOBIPHEP (20.8 mg; 0.032 mol) and 1.5-bis methylallylcyclooctadiene ruthenium (8.4 mg; 0.026 mol) in 1.5 ml of acetone. Hydrobromic acid in solution in methanol (0.0128 ml of a 0.5 M solution) was then added via syringe. This was left for 15 minutes at 20° C. under agitation.

[0168] This produced a catalytic solution of the complex [RuBr2(R)—CH3COOBIPHEP)]2 acetone.

EXAMPLE 11

Preparation of the Catalyst: the Complex Ru(R)-CH3COOBIPHEP) (OAc)2

[0169] The following was introduced into a 100-ml three neck flask under nitrogen: the ligand (R)—C H3COOBIPHEP (8 g) in toluene (50 ml).

[0170] Sodium acetate (4.48 g) and ruthenium cyclooctadiene dichloride (CODRuCl2) (3.85 g) were added.

[0171] Acetic acid (15.5 g) was added quickly. Heated at reflux (93° C.) for 22 hours.

[0172] Cooled to 65° C. Distilled under vacuum the azeotrope acetic acid/toluene. Repeated addition of toluene (40 ml) to bring the acetic acid to a residual volume of 20 ml.

[0173] Cooled to 50° C. and acetone was introduced (112 ml). It was allowed to cool to 20° C. and agitated for 1 hour.

[0174] Filtered and the filtrate was concentrated. The residue was taken up with toluene then concentrated (2 times 20 ml).

[0175] At 70° C. drop by drop addition under agitation of heptane (52 ml) (duration of the addition 52 minutes).

[0176] Allowed to cool to 20° C.

[0177] Filtered and rinsed with heptane (2 times 20 ml). Dried under bell.

[0178] This produced dark green crystals.

[0179] Yield: 30.2%.

[0180] Elemental analysis: 58.6% C; 4.6% H.

EXAMPLE 12

Preparation of the Catalyst: the Complex Ru(r)-(C H3)2CHCOOBIPHEP) (OAc)2

[0181] The same procedure as in example 11 was followed. Dark green crystals were obtained.

[0182] Yield: 83%.

[0183] Examples 13 to 19 followed the same procedure as in example 10.

III—Application in Asymmetric Hydrogenation

EXAMPLE 20

Asymmetric Hydrogenation of Ethylbenzoylacetate. Ligand of the Catalyst: A /insert formulas, bottom of page 20/

[0184] To the catalytic solution of example 10 were added ethyl benzoylacetate (0.5 g; 0.0026 mol) and 5 ml of ethanol. This was placed under a pressure of 20 bar of hydrogen. The medium was heated to 50° C. and left for 22 hours under agitation.

[0185] The medium was concentrated.

[0186] This produced 0.54 g of product in the form of a brown liquid.

[0187] Yield: Chemical purity: 82%.

[0188] Enantiomer excess: 97.8%

EXAMPLES 21 to 23

[0189] Same Operating Procedure as that of Example 20 with Ligands B, C or D

			Operating		Enantiomer
Example	L*ligand	Catalyst	conditions	Yield	excess
21	B	[RuL*Br2]	Substrate/		95.7
			catalyst = 100
22	D	[RuL*Br2]	idem		95.8
23	C	[RuL*Br2]	idem		96.2

EXAMPLE 24

Asymmetric Hydrogenation of the Hydroxyacetone Compound Ligand A.

[0190] 2

[0191] The same procedure as in example 20 was performed employing the indicated hydrogen pressure, temperature and substrate/catalyst ratio (S/C) in the reaction.

[0192] The anticipated product was obtained in the form of a brown liquid.

[0193] Yield: Chemical purity: 72.7%

[0194] Enantiomer excess: 96.1%

EXAMPLES 25 to 33

Same Operating Procedure as in Example 24 with the Ligands B, C, D, E, F, G or H. Catalyst [RuL*Br2]

[0195]

		Substrate/		Enantiomer
Example	L*ligand	catalyst	Yield	excess
25	B	1/3000	Quantitative	95.7
26	D	1/3000	idem	95.8
27	C	1/3000	idem	96.2
28	A	1/1000	idem	95.5
29	C	1/1000	idem	96.1
30	E	1/1000	idem	96.6
31	F	1/1000	idem	96.5
32	G	1/1000	idem	95.5
33	H	1/1000	idem	96.6

EXAMPLE 34

Asymmetric Hydrogenation of the Hydroxyacetone Compound

[0196] 3

[0197] The same procedure as in example 20 was performed employing the indicated hydrogen pressure, temperature and substrate/catalyst ratio (S/C) in the reaction.

[0198] The anticipated product was obtained in the form of a brown liquid.

[0199] Yield: 80-95%

[0200] Enantiomer excess: 97%

EXAMPLES 35 to 39

Same Operating Procedure as in Example 34 with the Ligands B, C, D, E, F, G or H. Catalyst [RuL*Br2]

[0201]

				Enantiomer
	Example	L*ligand	Yield	excess
	35	C	80-95%	97.2
	36	E	idem	97.6
	37	F	idem	97.2
	38	G	idem	97.9
	39	H	idem	97.5

EXAMPLE 40

Asymmetric Hydrogenation of the 4-Chloroacetoacetate Compound

[0202] 4

[0203] The same procedure as in example 20 was performed employing the indicated hydrogen pressure, temperature and substrate/catalyst ratio (S/C) in the reaction.

[0204] The anticipated product was obtained in the form of an oil.

[0205] Yield: quantitative.

[0206] Chemical purity: 52%.

[0207] Enantiomer excess: 94%.

EXAMPLE 41

Same Operating Procedure as in Example 40 with Ligand B Catalyst [RuL*Br2]

[0208]

			Substrate/		Enantiomer
Example	L*ligand	Catalyst	catalyst	Yield	excess
41*	B	[RuL*Br2]	1/4000	Quanti-	98.4
				tative
*temperature condition: 75° C.

EXAMPLE 42

Asymmetric Hydrogenation of the N-[1-(2-Naphthalenyl) Ethenyl]Acetamide Compound. Ligand A

[0209] 5

[0210] The same procedure as in example 20 was performed employing the indicated hydrogen pressure, temperature and substrate/catalyst ratio (S/C) in the reaction.

[0211] The anticipated product was obtained in the form of an orange oil.

[0212] Yield: 80-90.

[0213] Enantiomer excess: 85.8%.

EXAMPLES 43 to 47

Same Operating Procedure as in Example 42 with the Ligands B, C, E, F, and G. Catalyst [RuL*Br2]

[0214]

				Enantiomer
	Example	L*ligand	Yield	excess
	43	B	80-90%	87.5%
	44	C	idem	91.2%
	45	E	idem	90.8%
	46	F	idem	88.7%
	47	G	idem	89.7%

EXAMPLE 48

Asymmetric Hydrogenation of the Dimethyl Itaconate Compound Ligand A.

[0215] 6

[0216] The same procedure as in example 20 was performed employing the indicated hydrogen pressure, temperature and substrate/catalyst ratio (S/C) in the reaction.

[0217] The anticipated product was obtained in the form of a brown liquid.

[0218] Yield: 80-90%.

[0219] Enantiomer excess: 97.4%.

EXAMPLES 49 to 53

Same Operating Procedure as in Example 48 with the Ligands C, E, F, G and H. Catalyst [RuL*Br2]

[0220]

				Enantiomer
	Example	L*ligand	Yield	excess
	49	C	80-90%	97.6%
	50	E	idem	96.4%
	51	F	idem	97.7%
	52	G	idem	93.2%
	53	H	idem	97.3%

Claims

1. Use of an (R) or (S) chiral diphosphine of formula (I): /insert formula (I), top of page 26/

2. Use according to claim 1, characterized in that the diphosphino-metal complex responds to formula (II) below:

3. Use according to one of claims 1 or 2, characterized in that the diphosphino-metal complex responds to formula (IIA) below:

4. Use according to one of claims 1 to 3, characterized in that the diphosphino-metal complex is selected from among: Ru4Cl2[(R) or (S) CH3CHOO-Binap]2.N(Et)3, also designated di[2,2′-bis(diphenylphosphino) (R) or (S)-6,6′-diacetoxybiphenyl]-tetrachloro diruthenium triethylamine, Ru4Cl2((Me)2CHCOO-Binap)2.N(Et3), also designated di[2,2′-bis(diphenylphosphino) (R) or (S)-6,6′-di-isobutanoyloxybiphenyl]-tetrachloro diruthenium triethylamine, Ru4Cl2((CH3)3CCOO-Binap)2.N(Et)3, also designated di[2,2′-bis(diphenylphosphino) (R) or (S)-6,6′-ditrimethylacetoxybiphenyl]-tetrachloro diruthenium triethylamine, Ru4Cl2((Me)2CHCH2COO-Binap)2.N(Et)3, RU4Cl2(CH3COO-Binap)2.CO(Me)2, Ru4Br2(CH3COO-Binap)2.N(Et)3, Ru4Br2((Me)2CHCOO-Binap)2.N(Et)3, RU4Br2((CH3)3CCOO-Binap)2.N(Et)3, Ru4Br2((Me)2CHCH2COO-Binap)2.N(Et)3, Ru4Br2(CH3COO-Binap)2.CO(Me)2, Ru4Br2((Me)2CHCOO-Binap)2.CO(Me)2, Ru4Br2((CH3)3CCOO-Binap)2.CO(Me)2, Ru4Br2((Me)2CHCH3COO-Binap)2.CO(Me)2, Ru4Br2(C6H5COO-Binap)2.CO(Me)2, Ru4Br2(C6H11COO-Binap)2.CO(Me)2, Ru4Br2(C4H3OCOO-Binap)2.CO(Me)2, Ru4Br2(CH3OCH2COO-Binap)2.CO(Me)2,

5. Use according to one of claims 1 or 2, characterized in that the diphosphino-metal complex responds to formula (IIB) below:

6. Use according to claim 1, characterized in that the diphosphino-metal complex responds to formula (III) below:

7. Use according to claim 1, characterized in that the diphosphino-metal complex responds to formula (V) below:

8. Use according to claim 1, characterized in that the diphosphino-metal complex responds to formula (VI) below:

9. Use according to claim 1, characterized in that the diphosphino-metal complex responds to formula (VII) below:

10. Use according to claim 1, characterized in that the diphosphino-metal complex responds to formula (VIII) below):

11. Use according to claim 1, characterized in that the diphosphino-metal complex responds to formula (IX) below):

12. Use according to claim 1, characterized in that the diphosphino-metal complex responds to formula (X) below):

13. A diphosphino-metal complex of formula (II), (III), (V), (VI), (VII), (VIII), (IX) or (X) defined in one of claims 2 to 12.

14. Use of a diphosphino-metal complex according to claim 13 as catalyst in an asymmetric catalysis process.

15. Use according to claim 14, characterized in that the asymmetric catalysis process is an asymmetric isomerization process.

16. Use according to claim 14, characterized in that the asymmetric catalysis process is an asymmetric hydrogenation process.

17. Use of a diphosphino-metal complex according to claim 13 as catalyst in a process for asymmetric hydrogenation of unsaturated compounds carrying functional groups of formula (XVI) below: /insert formula (XVI), top of page 33/

18. Process for the asymmetric hydrogenation of a compound of formula (XVI) defined in claim 17, characterized in that it comprises the treatment of said compound of formula (XVI) in a suitable solvent in the presence of a complex according to claim 13 as catalyst.

19. Process according to claim 18, characterized in that the operating conditions are the following: A temperature between 0 and +150° C. A hydrogen pressure between 1 and 100 bar. An amount of catalyst in relation to the amount of compound of formula (XVI) comprised between 1/50,000 and 1/10, preferably between 10/10,000 and 1/10, and most preferably between 10/100 and 1/10.

20. Process according to one of claims 19 or 18, characterized in that the duration of hydrogenation is equal to or greater than 1 hour.

21. Process according to one of claims 18 to 20, characterized in that the concentration of the compound of formula (XVI) in the solvent is between 0.1 and 2 moles/liter.